CFO
IBRX icon

CVA Family Office’s ImmunityBio IBRX Stock Holding History

CVA Family Office’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.7K Buy
+308
New +$2.33K ﹤0.01% 1462

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CVA Family Office's IBRX Position: Q2 2026 in Review

CVA Family Office opened a new position in ImmunityBio (IBRX) in Q2 2026: 308 shares worth $2.7K. The stake represents ﹤0.01% of the portfolio and ranks #1462 among its holdings.

404 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • CVA Family Office held 308 shares of ImmunityBio worth $2.7K as of Q2 2026.
  • ImmunityBio was a new CVA Family Office position in Q2 2026.
  • ImmunityBio made up ﹤0.01% of CVA Family Office's portfolio in Q2 2026, its #1462 holding.
  • 404 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on CVA Family Office's 13F filing for Q2 2026, filed 7 Aug 2026.